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Abstract 
Sandhoff Disease (SD) is an autosomal recessive neurodegenerative disease caused by a mutation in the 
Hexb gene for the β-subunit of β-hexosaminidase A, resulting in the inability to catabolize ganglioside 
GM2 within the lysosomes. SD presents with an accumulation of GM2 and its asialo derivative GA2 
primarily in the CNS.  Myelin-enriched glycolipids, cerebrosides and sulfatides, are also decreased in SD 
corresponding with dysmyelination.  At present, no treatment exists for SD. Previous studies have 
shown the therapeutic benefit of using adeno-associated virus (AAV) vector-mediated gene therapy in 
the treatment of SD in murine and feline models. In this study, CNS tissue was evaluated from SD cats 
(4-6 week old) treated with bilateral injections of AAVrh8 expressing feline β-hexosaminidase α and β 
into the thalamus and deep cerebellar nuclei (Thal/DCN) or into the thalamus combined with 
intracerebroventricular injections (Thal/ICV). Both groups of treated animals had previously shown 
improved quality of life and absence of whole-body tremors.  The activity of β-hexosaminidase was 
significantly elevated whereas the content of GM2 and GA2 was significantly decreased in tissue 
samples taken from the cerebral cortex, cerebellum, thalamus, and cervical intumescence. Treatment 
also increased levels of myelin-enriched cerebrosides and sulfatides in the cortex and thalamus. This 
study demonstrates the therapeutic benefits of AAV treatment for feline SD and suggests a similar 
potential for human SD patients.  
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Introduction 
Gangliosides 
Gangliosides are a diverse group of acidic glycosphingolipids (GSL) containing one or more sialic acid 
units in the oligosaccharide chain. Gangliosides are the main components of neuronal plasma 
membranes where they help determine the surface properties of cells by contributing to the 
carbohydrate-rich glycocalyx [1]. Gangliosides are amphiphilic in nature and are composed of a 
hydrophobic ceramide moiety which anchors the molecule in the membrane [2] and a hydrophilic 
oligosaccharide chain with sialic acid attached to galactose subunits [3](Figure 1). First discovered by 
Ernst Klenk in the 1930s [4], 188 different ganglioside structures have since been identified in 
vertebrates [5](Yu et al., 2007). Kuhn and Wiegand elucidated the first ganglioside structure, GM1, in 
1963. Gangliosides vary in the complexity and composition of their carbohydrates as well as their sialic 
acids. The most common sialic acids found on gangliosides are N-acetylneuraminic acid (NeuNAc) and N-
glysolylneuraminic acid (NeuNGc) [1].  
Ganglioside Synthesis 
The ceramide residues of gangliosides are formed in the endoplasmic reticulum (ER) [6]. Glycosylation of 
ceramide, forming glucosylceramide (GlcCer) occurs at the Golgi and trans-Golgi network [7]. GlcCer is 
flipped to the luminal surface of the Golgi membrane where it is converted to lactosylceramide (LacCer). 
LacCer is sialylated to form the small precursor gangliosides GM3, GD3, and GT3 [6]. GM3, GD3, and GT3 
serve as precursors of more complex gangliosides via the addition of carbohydrate moieties catalyzed by 
a series of glycosyltransferases [8] (Figure 2).Completed gangliosides are shuttled via vesicular transport 
to the plasma membrane. 
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Ganglioside Catabolism 
The degradation of gangliosides occurs in the lysosomes where exohydrolases remove monosaccharide 
units from the end of the oligosaccharide chain [9] (Figure 3). Gangliosides from the plasma membrane 
are endocytosed and transported to the lysosomal compartment via the early and late endocytic 
reticulum [10]. Gangliosides in the lysosome are embedded on the lysosolic side of small intra-lysosomal 
vesicles. Water-soluble hydrolases remove ganglioside sugar residues that extend into the lumen of the 
lysosome. Gangliosides with less than four sugar residues require a sphingolipid activator protein (SAP) 
to aid in the removal of sugar residues near the hydrophobic membrane [9]. When mutations occur that 
disrupt hydrolyzing enzymes, ganglioside storage diseases occur [11]. 
Ganglioside Function 
Gangliosides are ubiquitously found in tissue and body fluids with the greatest abundance found in the 
nervous system [7]. They are generally localized to the outer leaflets of the plasma membrane. 
Gangliosides are involved in cell-to-cell recognition and adhesion, and signal transduction within cell 
surface microdomains called caveolae [12]. Gangliosides on nuclear membranes have been proposed to 
play roles in maintaining calcium homeostasis [13].  Gangliosides have also been shown to interact with 
toxins, bacteria, and viruses [14-16].  
GM2 Gangliosidoses 
The GM2 gangliosidoses are a group of inherited lysosomal storage disorders resulting in the abnormal 
storage of ganglioside GM2 and its asialo derivative GA2. The diseases are caused by mutations in one of 
three genes: HEXA, HEXB, or GM2A. HEXA and HEXB code for the α and β subunits of the hydrolyzing 
enzyme β-hexosaminidase. These subunits dimerize to produce two major isoenzymes of β-
hexosaminidase, Hex A and Hex B, and one minor isoenzyme, Hex S. Hex A is composed of an α and β 
subunit, Hex B consists of a homodimer of β subunits and Hex S, consists of a homodimer of α subunits.  
GM2A codes for the GM2 activator protein that acts as a substrate-specific cofactor. Hydrolysis of GM2 
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requires both Hex A and the GM2 activator protein [11]. Three forms of GM2 gangliosidosis result from 
mutations in each of the three required genes. Tay-Sachs disease (variant B) results from mutations in 
HEXA, Sandhoff disease (SD) (variant O) results from mutations in HEXB, and GM2 activator deficiency 
(variant AB) results from mutations in GM2A [17].  
β-hexosaminidase 
The presence of N-acetyl-β-D-glucosaminidase in mammalian tissue was first reported in 1936 [18]. The 
enzyme was given the name β-hexosaminidase after it was shown to hydrolyze the β-glycosidic bond of 
N-acetyl-D-glucosamine and N-acetyl-D-galactosamine [19-25]. β-hexosaminidase is synthesized in the 
lumen of the ER, processed through the Golgi, and transported via the mannose 6-phosphate receptor 
to the lysosome. In the lysosome, β-hexosaminidase hydrolyzes glycoproteins, glycosaminoglycans and 
glycolipids [11].  
In order for water soluble β-hexosaminidase to cleave glycolipid substrates on membrane surfaces, the 
substrate must extend far enough into the aqueous phase [26]. β-hexosaminidase cannot hydrolyze 
GM2 in the membrane and thus requires the GM2 activator. The GM2 activator is a protonated cationic 
amphiphilic protein [6]that binds to the lysosomal membrane surface and acts as a liftase, bringing GM2 
out of the membrane. The activator then presents GM2 to β-hexosaminidase for degradation (Figure 4) 
[10]. 
Sandhoff Disease 
Sandhoff Disease is caused by inherited autosomal recessive mutations in the β subunit of β-
hexosaminidase. The resulting accumulation of GM2 and GA2 causes progressive neurodegeneration 
and brain dysfunction. The disease is also characterized by a reduction in myelin enriched lipids, 
cerebrosides and sulfatides[17, 27, 28]. SD is classified into three different forms according to the age of 
onset—, infantile, juvenile, and adult forms. Patients with infantile disease appear normal at birth, but 
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begin showing mild motor weakness at 3-5 months of age. Progressive weakness, loss of motor skills, 
difficulty swallowing, vision loss, macrocephaly, and seizures mark the progression of the disease, which 
eventually culminates at death, due to bronchopneumonia (Table 1) [11].  
Feline Model of SD 
Naturally occurring ganglioside storage diseases have been observed in man, cats, dogs, cattle, swine, 
and bear [29, 30]. Feline GM2 gangliosidosis variant 0 (Sandhoff disease) has been described in 
shorthaired domestic cats (fGM2Baker) [31], Korat cats (fGM2Korat) [32], Japanese domestic cats [33], 
and European Burmese cats [34]. Feline SD has several features in common with the human disease 
including the accumulation of GM2 and its asialo derivative GA2, progressive nervous system 
deterioration, the presence of membrane-bounded inclusions in the nervous system and viscera, a 
marked decrease in β-hexosaminidase activity in brain, liver, and skin fibroblasts, dismyelination and a 
reduction in myelin associated lipids (Figure 5), and an autosomal recessive mode of inheritance [31, 35, 
36]. At least 25 HEXB mutations have been found to cause SD in humans [37]. Examination of 
pathogenic HEXB mutations in SD cats found a 25-base-pair inversion in fGM2Baker animals [38](Martin 
et al., 2004), a deletion of cytosine #39 in Korat cats [39], a nonsense mutation (R223X) in Japanese 
domestic cats [40], and a 15bp deletion including an AG splice acceptor site in European Burmese cats 
[34]. Research using feline models of GM2 serves as an important bridge between murine research and 
human clinical trials. The feline brain is greater than 50 times larger than a mouse brain, significantly 
more complex and anatomically closer to human [41]. Human storage of GM2 and GA2 and loss of 
myelin-associated lipids are modeled better in the cat than mouse [36]. Disease onset in humans is also 
more closely paralleled to disease onset in cats. Mice develop symptoms around 12 weeks of age, past 
the age of sexual maturity. Both humans and cats succumb to the disease prior to sexual maturity [36].  
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Treatment of SD 
Although the cause of SD has been known for several years, the disease remains without cure today. 
Enzyme replacement therapies have been successful at treating non-neuropathic lysosomal storages 
diseases such as type 1 Gaucher Disease[42], but similar treatment of lysosomal storage disorders 
affecting the CNS is restricted by the blood-brain-barrier (BBB). The BBB prevents the delivery of 
exogenous enzymes to the CNS obstructing the therapeutic effects of most enzyme replacement 
therapies [43, 44](Johnson et al., 1973; Von Specht et al., 1979). Some enzyme replacement therapies 
are able to circumvent the BBB but their effects on the levels of storage material are minimal 
[45](Rattazzi et al., 1982). Several other experimental gangliosidosis therapies have been examined in 
the treatment of SD including bone marrow transplantation, stem cell therapy, substrate reduction 
therapy, calorie restriction, and gene therapy [27, 41, 46-50]. 
AAV-gene therapy 
Gene therapy is used to treat lysosomal storage disorders by incorporating the genes of interest, into a 
viral vector delivery system, then administering the vector to the host. For the treatment of SD, HEXA 
and HEXB are integrated into vectors. Integration of HEXA prevents overexpression of HEXB from rapidly 
depleting the pool of endogenous α subunits [51]. The most prominent CNS gene delivery vector is 
currently adeno-associated virus (AAV) [52]. AAVs are nonenveloped viruses consisting of a 4.7 kb single-
stranded genome with two open reading frames (ORF) flanked by inverted terminal repeat elements 
(ITR) [53]. The ORFs, cap and rep, encode for three structural proteins and four Rep proteins. Cap and 
rep can be completely excised from between the ITRs allowing for insertion of a gene of interest and 
recombinant promoters (Figure 6) [53]. The cytomegalovirus (CMV) promoter and the truncated chicken 
beta actin (CBA) promoter are commonly used promoters due to their strength and ability to promote 
ubiquitous expression [54]. Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) 
can also be added to the vector to further strengthen the promoter and prevent silencing [55].  
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AAVs have several desirable features as gene delivery vectors. Although AAVs naturally infect humans, 
the virus is nonpathogenic making it potentially safe [56]. Furthermore, all viral genes can be deleted 
from AAVs enhancing safety and transgene efficiency [53]. Finally, AAVs can transduce dividing and 
nondividing cells, causing long-term stable gene expression without inflammation or toxicity [56].  
After injection into a host the AAV binds to the cell surface, is taken into the cell, trafficked to the 
nucleus, uncoated and double stranded DNA is synthesized. The gene of interest is transcribed in the 
nucleus and translated into protein in the ER. Not all diseased cells acquire AAV integration. These cells 
rely on lysosomal enzyme trafficking, a phenomenon called cross-correction. Following post-
translational modification in the Golgi, the enzyme of interest is sent to the lysosomes or released into 
extracellular space. Extracellular enzymes are taken up by neighboring cells via the mannose-6-
phosphate pathway and targeted to the lysosomes (Figure 7) [57].  
Over 100 different AAV serotypes have been isolated from a variety of animal species. Studies have 
shown that serotypes exhibit different tissue or cell tropisms [58]. Additionally, pseudotyping, the cross-
packing of the genome from one serotype into the capsid of another, results in vectors with new 
tropisms [53]. Different serotypes and pseudotypes allow for idealized targeting of transduction.  
Previous AAV studies in SD cats 
Treatment of SD cats with AAV1 vectors expressing human β-hexosaminidase resulted in a reduction of 
GM2 ganglioside storage and an increased lifespan [41]. However, a pronounced humoral immune 
response was detected in treated cats. Second-generation vectors were developed, incorporating the 
AAVrh8 capsid and expressing feline β-hexosaminidase α and β (Figure 6). These vectors resulted in a 
similar reduction of GM2 and increase in longevity with a minimal immune response [41]. 
For this study, collaborators performed bilateral thalamus injections paired with deep cerebellar nuclei 
(DCN) injections or intracerebroventricular (ICV) injections of AAV2/rh8-CBA-fHexaWPRE and AAV2/rh8-
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CBA-fHexb-WPRE in juvenile SD cats.  Injection sites were chosen to promote maximum distribution of 
vector through the cerebrospinal fluid (CSF) and β-hexosaminidase through cross correction. 16 weeks 
post injection animals were sacrificed to assess β-hexosaminidase activity, ganglioside storage, and the 
concentration of myelin associated lipids in the cortex, cerebellum, thalamus, and cervical 
intumescence.  
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Figure 1. The structure and membrane orientation of GM2. A hydrophobic ceramide moiety anchors 
GM2 to the outer leaflet of the plasma membrane. The hydrophilic oligosaccharide chain composed of 
glucose, galactose, n-acetyl galactosamine, and n-acetylneuraminic acid extends into the extracellular 
space. Adapted from themedicalbiochemistrypage.org 
 9 
 
 
 10 
 
Figure 2. Structures and biosynthetic pathways of gangliosides. The ganglioside nomenclature is based 
on that of Lars Svennerholm [59]. Cer, Ceramide; GalT, Galactosyltransferase; ST, Sialyltransferase; GlcT, 
Glucosyltransferase; GalNacT, N-acetylgalactosaminyltransferase. [60] 
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Figure 3. Ganglioside catabolism. Exohydrolases remove monosaccharide units from the 
oligosaccharide chain of gangliosides. In the “classical” pathway GM2 is hydrolyzed to GM3 by Hex A and 
the GM2 activator protein. In the “alternative” pathway  GM2 is converted to GA2 by a sialidase. 
Mutations in Hex A or GM2 activator protein inhibit the degradation of GM2 and GA2 causing 
accumulation of these molecules in the lysosomes. 
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Figure 4. Hydrolysis of GM2 requires Hex A and the GM2 activator protein. The GM2 activator protein 
lifts GM2 from the hydrophobic membrane and forms a complex with water-soluble β-hexosaminidase A 
[9]. 
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Table 1. The main clinical hallmarks and symptoms in GM2 gangliosidoses
Disease Manifestation Regular symptoms/signs Facultative symptoms/signs
GM2-gangliosidosis, 
variants B and 0
Infantile Loss of head/trunk control, smiling, by about 6 
months, cherry-red macular spot, high startle 
response to noise, muscle hypotonia by 1 year, 
epilepsy, tetraparesis with some spasticity, 
dementia, blindness
Megalencephaly, visceral involvement and 
oligosacchariduria only in variant 0
Juvenile/subacute Onset by 3 to 6 years, dysarthria, loss of speech, 
spastic paraparesis, later on paraplegyf, pyramidal 
signsf, cerebellar ataxia, mental deterioration
Seizures, irritability, psychiatric signs, denervation 
muscle atrophy (EMG), areflexia, cherry red macular 
spot
Adult Clumsiness, lower motor neuron disease, 
denervation muscle atrophy, cerebellar ataxia
Psychosis
Chronic
GM2-gangliosidosis, 
variant AB
Most as in variants B and, 0 Cherry red macular spot
Adapted from Sandhoff and Harzer, 2013
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Figure 5. Dysmyelination in Sandhoff cats. MR images from 10.5 week healthy (A) and SD (B) Korat cats. 
Signal hypointensity, relative to the control, is supportive of diminished myelination [35]. 
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Figure 6. The recombinant AAV shuttle vector. The AAV genome contains two open reading frames, 
encoding 4 viral replication (Rep) proteins and 3 structural (Cap) proteins. The ORFs are flanked by 5’ 
and 3’ inverted terminal repeats (ITRs). The ORFs are excised allowing for the insertion of a gene of 
interest and recombinant promoters.  Recombinant AAV shuttle vectors express HEXA or HEXB with a 
CBA promoter and WPRE. Adapted from Romano, 2005 [61]. 
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Figure 7. Lysosomal enzyme trafficking and cross-correction. Glycosylated lysosomal enzymes (green 
circles) acquire the mannose 6-phosphate modification (red circles) in the Golgi apparatus where they 
bind the mannose 6-phosphate receptor (M6PR). The majority of the enzymes are then trafficked to the 
mature lysosome while a small minority are secreted from the cell. Extracellular enzyme can bind the 
plasma membrane-localized M6PR. Binding mediates endocytosis and subsequent lysosomal targeting 
of the exogenous enzymes. ER, endoplasmic reticulum; Lys, Lysosome; ManR, mannose receptor (found 
only in fixed tissue macrophages).[57] 
 
  
 22 
 
 
 
  
 23 
 
Materials and Methods 
The production of AAV vectors as well as the treatment and care of the cats were performed by 
collaborators.  
Cats 
All cats were cared for and treated at the College of Veterinary Medicine, Auburn University. AAV gene 
therapy was delivered by as previously described [41]. Briefly, 4-6 week old cats were anesthetized with 
ketamine and dexmedetomidine and maintained with isofluorane in oxygen. Stereotaxic vector delivery 
was performed using a Horsley-Clark stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). The 
thalamus was injected bilaterally with a 20G hypodermic needle. 70 μl was injected in 10-20 μl aliquots 
at a rate of 2 μl/minute. The injection needle was raised 0.15 cm between each aliquot so the final 
needle position was 1.15 cm ventral to meninges. For each DCN a total of 20 μl was injected at a single 
site at a rate of 2 μl/minute [41]. Intracerebroventricular injections were performed in the left lateral 
ventricle. 200 μl was injected in 15 μl boluses with 1 minute separating each bolus. Animals were 
euthanized 16 weeks post-injection by pentobarbital overdose (100 mg/kg). Animals were then perfused 
with cold heparinized saline and brains were divided into coronal blocks of 0.5 cm from the frontal pole 
through the cerebellum. 
AAV vectors 
Feline HEXA and HEXB cDNA was amplified as previously described [41] PCR products were cloned into 
pAAV-CBA-MBG-W. Expression of the vectors is mediated by the hybrid CBA promotor and the 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). Production of AAVrh8 vector 
stocks encoding feline hexosaminidase α and β was described previously. [62] 
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Lipid Extraction 
CNS tissue was homogenized in 3.0 ml dH2O. An aliquot (100 μl) of each homogenate was set aside for 
analysis of β-hexosaminidase activity. The remaining homogenate was frozen at -80°C and lyophilized. 
The weight of the lyophilized tissue was measured prior to lipid extraction.  
Lyophilized tissue were transferred into 50 ml glass screw capped test tubes and rehydrated with 0.5 ml 
of dH2O. Lipids were extracted from the tissue by adding 5.0 ml CHCl3: CH3OH 1:1 (v/v). A small magnetic 
stirring bar was added and samples were placed on a magnetic stirrer at room temperature overnight 
[63, 64]. Samples were spun at 1200 x g for 20 minutes and the supernatant was collected. 2.0 ml CHCl3: 
CH3OH 1:1 (v/v) was added to the pellets prior to spinning a second time. The second supernatant was 
collected and added to the first. 2.5 ml of chloroform, 8.5 ml of methanol, and 1.6 ml dH20 were added 
to the supernatant creating a final ratio of 30:60:8 CHCL3: CH3OH: dH2O (v/v/v) [65]. 
Column Chromatography 
Ion exchange chromatography was performed to separate neutral lipids and cholesterol from acidic 
lipids and gangliosides as previously reported [36, 66]. Total lipid extract was applied to a column 
containing DEAE sephadex (A-25, GE Healthcare). The column was washed twice with 20 ml of solvent A, 
CHCl3: CH3OH: dH2O 30:60:8 (v/v/v) and the entire neutral lipid fraction consisting of the initial eluent 
plus washes was collected. This fraction contained the cholesterol, phosphatidylcholine, 
phosphatidylethanolamine, plasmalogens, sphingomyelin, cerebrosides and asialo-GM2 (GA2). The 
column was then washed with 30 ml of solvent B, CHCl3: CH3OH: 0.8M Na acetate 30:60:8 (v/v/v) in 
order to elute and collect acidic lipids and gangliosides. 
Neutral Lipid Purification 
Neutral lipids were dried by rotarty evaporation and resuspended in 10 ml CHCl3:CH3OH 1:1 (v/v). To 
further purify GA2, a 4 ml aliquot of neutral lipid was dried under nitrogen then base treated with 1 ml 
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of 1 N NaOH at 37°C for 1.5 hours. The sample was Folch partitioned as previously described 
([67]Kasperzyk et al., 2004). The lower phase containing GA2 and cerebrosides was evaporated under 
nitrogen and resuspended in 4.0 ml CHCl3:CH3OH 1:1 (v/v) [36].  
Ganglioside and Acidic Phospholipid Purification 
The acidic lipid fraction containing gangliosides was dried by rotary evaporation and separated into 
acidic lipids and gangliosides by Folch partitioning as described previously [63, 68, 69]. After the upper 
aqueous phase containing gangliosides was transferred, the lower organic phase containing the acidic 
lipids was dried under nitrogen and resuspended in 10 ml CHCl3:CH3OH 1:1 (v/v). This fraction contained 
fatty acids, cardiolipin, phosphatidylserine, phosphatidylinositol, and sulfatides.  
Resorcinol Assay 
An aliquot of the upper aqueous phase containing gangliosides was evaporated and analyzed for sialic 
acid content using a resorcinol assay as previously described [64, 67, 70]. N-acetylneuraminic acid was 
used as an external standard. Samples were dissolved in 1.0 ml of resorcinol reagent (40 ml 
concentrated HCl, 0.125 ml 0.1 M copper sulfate, 5 ml 2% resorcinol stock, brought up to 50 ml with 
dH2O): dH2O 1:1 (v/v). Samples were then boiled for 17 minutes and cooled in an ice bath. 1.5 ml of 
butyl acetate: 1-butanol 85:15 (v/v) was added to each sample. Samples were vortexed then centrifuged 
at 1200 x g for 1 minute. The violet supernatant was removed and analyzed at 580 nm in crystal cuvettes 
in the Shimadzu UV-1601 UV-visible spectrophotometer (Shimadzu, Kyoto, Japan).  
Base Treatment and Desalting 
The remaining gangliosides were evaporated under nitrogen. Dried gangliosides were base treated with 
1 ml of 1 N NaOH at 37°C for 1.5 hours. Salts were removed from gangliosides using a C18 reverse-phase 
Bond Elute column as previously described [64, 65, 67]. The samples were applied to columns that were 
previously equilibrated with 5 ml each of: CHCL3:CH3OH 1:1 (v/v), CH3OH, and 0.1M NaCl. The columns 
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were washed slowly with 20 ml dH20 to remove salts. Gangliosides were eluted from the columns using 
4 ml CH3OH followed by 3 ml CHCL3:CH3OH 1:1 (v/v) then dried under nitrogen. Gangliosides were 
resuspended in 5 ml CHCL3: CH3OH 2:1 (v/v) and an aliquot was analyzed for sialic acid content. 
Lipid Analysis by HPTLC 
All lipids were evaluated qualitatively with high-performance thin layer chromatography (HPTLC). Each 
lane was spotted with 1.5 μg sialic acid for gangliosides, 70 μg of dry weight for neutral lipids, and 200 
μg of dry weight for acidic lipids and GA2. Purified lipid standards were purchased from Matreya, Inc. 
(Pleasant Gap, PA) or were a gift from Dr. Robert Yu (Medical College of Georgia, August, GA). To 
enhance precision, oleoyl alcohol was added as an internal standard to the neutral and acidic lipid 
standards and samples. Lipids were spotted on 10 x 20 cm Silica gel HPTLC plates using a Camag Linomat 
V semi-automatic TLC spotter (Camag Scientific Inc., Wilmington, NC). Gangliosides were developed in a 
single ascending run for 90 minutes in CHCL3: CH3OH: dH2O 55:45:10 (v/v/v) containing 0.02% CaCl2 (aq). 
Plates were sprayed with resorcinol-HCl reagent and heated at 95°C face down for 10 minutes then face 
up for an additional minute in order to visualize gangliosides [63, 71]. GA2 was developed to the top in a 
single ascending run in CHCL3:CH3OH:dH2O 65:35:8 (v/v/v) containing 0.22% CaCl2 (aq). Plates were 
sprayed with orcinol-H2SO4 and heated at 95°C face up for 5 minutes to visualize GA2 [70]. Neutral and 
acidic lipid HPTLC plates were developed to a height of 4.5 or 6 cm respectively in CHCL3:CH3OH: 
CH3COOH:CHOOH:dH2O 35:15:6:2:1 (v/v/v/v/v). Plates were dried then developed to the top in 
C6H14:C6H14O:CH3COOH 65:35:2 (v/v/v). Lipid bands were visualized by charring with 3% cupric acetate in 
8% phosphoric acid solution for 7 minutes as previously described [67, 72]. 
Quantitation of Individual Lipids 
The quantitation of individual lipids was performed as previously described [50]. Total brain ganglioside 
distribution was normalized to 100% and the percentage distribution was used to calculate sialic acid 
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concentration of GM2. To calculate neutral lipids, acidic lipids and GA2 density values were fit to a 
standard curve of known standard.  
β-hexosaminidase Assay 
β-hexosaminidase activity was determined as previously described [64].  Aliquots of brain homogenate 
were centrifuged for 5 minutes at 2000x g. 40 μl of each supernatant was added in duplicate to 96-well 
microplates on ice. 40 μM 4-methylumbelliferone (Sigma-Aldrich, St. Louis, MO) in 0.9% NaCl was 
aliquoted in increasing volumes as a standard. 20 μl of 1.0 mM 4-methylumbelliferyl N-acetyl-β-D-
glucosaminide was added as a substrate to tissues and standards. The plates were then incubated for 30 
minutes at 37°C. The reaction was stopped by the addition of 200 μl of 0.5M Sodium Carbonate (pH 
10.7). Fluorescent emission was determined by a SpectraMax M5 micro-plate reader (Molecular 
Devices, Sunnyvale, CA). Excitation and emission were set at 355 nm and 460 nm, respectively. Specific 
β-hexosaminidase activity was expressed as nmol/mg protein/hr.  
Total protein concentrations were determined with Bio-Rad protein assay (Bio-Rad, Hercules, CA) based 
on the Bradford method [73].  Briefly, 10 μl of each sample supernatant was added in duplicate to 96 
well plates on ice. Bovine serium albumin (BSA) (Sigma-Aldrich, ST. Louis, MO) was aliquoted in 
increasing concentrations as a standard. Bio-Rad Protein Dye Reagent 200 μl: dH20 1:4 (v/v) was added 
to each well and plates were incubated at room temperature for 15 minutes. The plates were analyzed 
in the SpectraMax M5 at 595 nm. 
Statistics 
All data were analyzed by one-way ANOVA to calculate statistical significance between groups using IMB 
SPSS Statistics 21 software. 
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Results 
Our objective was to quantify changes in lipid storage in various CNS regions of AAV-treated Sandhoff 
disease cats at 16 weeks post- injection to understand the neurochemical basis of the remarkable 
therapeutic benefit recently reported for these animals (Bradbury et al, 2013).  In order to determine 
the distribution of β-hexosaminidase from the injection site to other regions of the brain, enzyme assays 
were performed for each region of the CNS examined. While little β-hexosaminidase activity was 
detected in the untreated SD cats, activity was 2-10 fold greater in all regions of the AAV treated cats 
than in the normal cats (Table 2). Enzyme activity was found to be the highest in the thalamus, the site 
of injection, and in the spinal cord. Thal/ICV injections generated greater enzyme activity than Thal/DCN 
injections in all four regions.  
Thal/ICV AAV treatment reduced total ganglioside concentration by 62%, 38%, 62% and 66% in the 
cortex, cerebellum, thalamus and spinal cord regions, respectively. Thal/DCN treatment reducted total 
ganglioside concentration by 50%, 36%, 63%, and 45% in cortex, cerebellum, thalamus, and spinal cord, 
respectively. (Table 2).  The sialic acid concentration in all four regions of the treated animals remained 
higher than the concentration in normal animals regardless of which treatment, but the elevation was 
not statistically significant.  
GM2 accounted for approximately 40% of the total ganglioside in the various CNS regions of SD cats.  
Treatment with Thal/ICV AAV injections resulted in a 92% or greater decrease of GM2 storage in all CNS 
regions tested with a 98% decrease in the thalamus (Fig 8). Treatment with Thal/DCN injections resulted 
in a 72% or greater decrease of GM2 storage in all regions tested with a 99% decrease in the thalamus. 
Correction of GM2 storage varied for each animal tested as well as between regions for each individual 
cat. In some animals AAV treatment decreased GM2 concentration to below detectable levels as seen in 
the normal cats.  
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Similar correction was seen in the levels of asialo GM2 (GA2). GA2 was undetectable in the CNS regions 
examined in normal cats, but was a major storage material in SD cats.   AAV treatment reduced GA2 to 
undetectable levels in the thalamus of SD cats and significantly reduced storage in all other regions 
(Table 2). Two Thal/ICV treated animals had no detectable GA2 accumulation in any of the regions 
tested (data not shown for individual animals) while the remaining cats varied in the amount of GA2 
from 241 μg/100 mg dry weight to undetectable levels.  
The concentration of cerebrosides and sulfatides was significantly lower in the brain regions of 
untreated SD cats than in the same regions of normal cats (Table 2, Figures 9 and 10). This is consistent 
with previous reports of lower myelin-enriched glycolipids in SD mice, cats, and humans [17, 36]. Both 
treatments partially restored the levels of cerebrosides and sulfatides in the cortex region as well as the 
levels of sulfatides in the thalamus. Thal/ICV treatment restored cerebroside levels in the thalamus, but 
Thal/DCN treatment had no effect on restoring these levels. Neither treatment was able to restore 
cerebroside or sulfatide levels in the cerebellum (Table 2). No differences were found for the 
concentration of cerebrosides or sulfatides in the spinal cord between normal and SD cats regardless of 
treatment.  
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Figure 8. HPTLC of gangliosides from Sandhoff cat cortex, cerebellum, thalamus, and cervical 
intumescence. Gangliosides from normal cats (N), Sandhoff disease cats (SD), and Sandhoff disease cats 
treated with AAV vectors were separated in a single ascending run with CHCl3:CH3OH;dH20, 55:45:10 
(v/v/v) with 0.02% CaCl2. 1.5 μg of sialic acid was spotted for each sample. The bands were visualized 
with the resorcinol-HCl spray.  
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Figure 9. HPTLC of neutral lipids from Sandhoff cat cortex, cerebellum, thalamus, and cervical 
intumescence. The plate was developed to a height of 4.5 cm with CHCL3:CH3OH: 
CH3COOH:CHOOH:dH2O 35:15:6:2:1 (v/v/v/v/v) then developed to the top with C6H14:C6H14O:CH3COOH 
65:35:2 (v/v/v). The amount of neutral lipid spotter per lane was equivalent to 70 μg tissue dry weight. 
The bands were visualized by charring with 3% cupric acetate in 8% phosphoric acid solution. CE, 
cholesterol esters; TG, triglycerides; IS, internal standard (oleyl alcohol); Chol, cholesterol; Cer, 
ceramide; CB, cerebrosides (doublet); PE, phosphatidylethanolamine; PC, phosphatidylcholine; SM 
sphingomyelin; LPC, lysophosphatidylcholine. 
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Figure 10. HPTLC of acidic lipids from Sandhoff cat cortex, cerebellum, thalamus, and cervical 
intumescence. The plate was developed to a height of 6 cm with CHCL3:CH3OH: CH3COOH:CHOOH:dH2O 
35:15:6:2:1 (v/v/v/v/v) then developed to the top with C6H14:C6H14O:CH3COOH 65:35:2 (v/v/v). The 
amount of neutral lipid spotter per lane was equivalent to 200 μg tissue dry weight. The bands were 
visualized by charring with 3% cupric acetate in 8% phosphoric acid solution. FA, fatty acids; IS, internal 
standard (oleyl alcohol); CL, cardiolipin; PA, phosphatidic acid; Sulf, sulfatides (doublet); PS, 
phosphatidylserine; PI, phosphatidylinositol. 
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Discussion 
At present, no effective treatment exists for Sandhoff disease. While several treatments have been 
examined, few have the therapeutic effects of AAV mediated gene replacement. Recent studies in 
murine and feline models have shown the potential for AAV treatment in the management of 
ganglioside storage diseases [41, 42, 49, 51, 65, 74, 75]. Here, I examined the effects of thalamic 
injections, in combination with either DCN or ICV injections, of AAV2/rh8 expressing feline β-
hexosaminidase α and β on the lipid concentrations in different regions of the SD cat central nervous 
system (CNS).  
Vector serotype and injection locations were chosen to promote the efficacy of AAV treatment. The 
AAV8 vector was evaluated, as it has been shown to be more efficient than other vectors at achieving 
widespread gene delivery [62]. Previous studies revealed that axonal transport could facilitate delivery 
of lysosomal enzymes throughout the CNS [76, 77]. In order to maximize the distribution of β-
hexosaminidase from vector-transduced cells, the highly interconnected thalamus and DCN were chosen 
as the sites for AAV injection [65, 78, 79]. ICV injections were chosen to delivery AAV directly into the 
CSF allowing the vector to travel throughout the CNS [80]. In this study, assays for the specific activity of 
β-hexosaminidase revealed that thalamic delivery paired with DCN or ICV delivery of an AAV vector is an 
effective approach to achieve widespread delivery of enzyme throughout the tested regions of the CNS. 
Enzyme activity in all regions was 2-10 times greater in treated animals than normal animals and over 50 
times greater in the treated SD animals than in the untreated SD animals. The highest level of enzymatic 
activity occurred in the thalamus, the location of injection. The significantly higher levels of β-
hexosaminidase activity in cats receiving Thal/ICV injections compared to Thal/DCN injections can be 
attributed to a greater amount of vector injected into the ICV than the DCN. While other studies using 
AAVs have reported brain toxicity caused by overexpression of proteins [81] [82], previous study using 
this vector found no evidence of neuron loss or clinical neurological symptoms in cats >1 year post-
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injection indicating no brain toxicity as a result of AAV-mediated overexpression of protein [41]. For this 
reason I do not believe that the high levels of enzyme cause cytotoxicity despite significant elevation of 
β-hexosaminidase in treated cats. 
The storage of GM2 and GA2 in SD causes lysosomal swelling, cellular apoptosis and CNS inflammation 
[75, 83, 84]. In order to prevent neuronal loss, SD treatment must decrease lipid storage in the 
lysosomes. When examining SD cats massive storage of GM2 was found in all tested regions, yet the 
percent distribution of GM2 was similar among all of the tissues assayed, despite their differences in 
ganglioside sialic acid content. Treatment with AAV decreased GM2 storage as well as GA2 storage by 
greater than 72% in all regions tested for both Thal/ICV and Thal/DCN treatments. This decrease in lipid 
storage indicates that the therapeutic effect of AAV treatment is fairly consistent between brain regions. 
Such reduction should slow or alleviate disease progression. The improvement in quality of life 
previously reported [41] supports this notion. 
Although gangliosides are mostly stored in CNS gray matter, histopathologic changes have been seen in 
white matter of mice, cats, and humans with SD [35, 36, 85]. In addition to these changes, myelin 
associated lipids, cerebrosides and sulfatides are also decreased in mice, cats, and humans with SD [17, 
36]. These findings suggest that dysmyelination contributes to SD pathogenesis [86]. Our results showed 
that AAV treatment partially restored the reduction of cerebrosides and sulfatides in the cortex and 
thalamus regions. The lack of correction in the cerebellum and spinal cord despite reduced ganglioside 
storage requires further investigation. The high level of variability between animals may be masking any 
cerebroside or sulfatide correction in these regions. MR imaging of treated cat’s brains could be utilized 
to further examine myelin and elucidate our understanding. 
The differences found for total ganglioside concentration between the various regions of the cat brain 
are consistent with observations from previous studies [28, 87, 88]. Interestingly, each animal that was 
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evaluated seemed to respond to AAV treatment differently. While a significant amount of correction 
was seen in each region of every animal, the amount of remaining storage material varied between cats. 
The variability in regional ganglioside sialic acid concentration could explain how treatment cleared 
storage in CNS regions of some cats, but not in other cats.  Similar ganglioside sialic acid variations were 
seen in the brains of human SD patients [36]. These variations may cause different levels of therapeutic 
success if AAV mediated gene therapy were to be utilized in the treatment of human SD patients.  
Little statistical difference was observed between Thal/ICV and Thal/DCN treatments. Both treatments 
decreased total ganglioside content and storage material as well as partially restore myelin-enriched 
glycolipids. Although enzyme activity was significantly greater in the Thal/ICV treated cats than the 
Thal/DCN treated cats, the reduction of storage material after Thal/ICV treatment was not statistically 
greater than the reduction after Thal/DCN treatment. Further investigation of other regions of the brain, 
particularly the lumbar intumescence, should be performed in order to illuminate any significant 
differences that may exist between these two treatments.  
This study shows the effectiveness of AAV vector gene therapy in attenuating the major lipid 
abnormalities in SD cats. While the initial data are promising, the long-term effects of the treatment are 
still being examined. Examination of the enzyme activity and lipid concentrations of long term survival 
animals will allow for the assessment of the therapeutic benefit in the long term and better plan for a 
transition into human treatment.  
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